美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Neuroscience and Healthcare ETF

40.36

+0.25780.64%

成交量：1,675

成交額：6.74萬

市值：807.24萬

市盈率：- -

高：40.70

開：40.70

低：39.63

收：40.10

52周最高：43.01

52周最低：24.96

股本：20.00萬

流通股本：20.00萬

量比：1.01

換手率：0.84%

股息：0.32

股息率：0.79%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

西藏首家高原腦機接口臨床應用中心成立

資本瘋搶、玩家扎堆，腦機接口真的要來了？

阿爾凱默斯與安尼爾終止授權仿製藥供應協議

阿爾凱默斯與安尼爾協議終止後，無需承擔罰金或額外義務——SEC文件披露

Praxis Precision Medicines與Remagine Labs宣佈戰略合作，開發治療特發性震顫的透皮烏利沙卡他胺

國內首款硬膜下植入式腦機接口產品啓動註冊臨床試驗，宣稱不傷腦、不燒腦

上半年上海腦機接口融資事件數量佔全國近60%

「站在未來看今天，應做對什麼」

明視腦機陳文凱：感知重建視覺重建是腦機接口領域的「珠穆朗瑪峯」

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/IBRN/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":40.3622,"timestamp":1787774400000,"preClose":40.1044,"halted":0,"volume":1675,"delay":0,"changeRate":0.006428222339693479,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"盤前交易","change":0.2578,"latestTime":"08-27 06:15:15 EDT","open":40.7,"high":40.7,"low":39.63,"amount":67407,"amplitude":0.02668,"askPrice":64.17,"askSize":100,"bidPrice":37.05,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787837400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":40.3622,"sharesOutstanding":150000,"nav":40.140891,"aum":8028178.2,"dividendRate":0.007901,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":40.47,"preClose":40.3622,"latestTime":"16:10 EDT","volume":6,"amount":242.1732,"timestamp":1787775004785,"change":0.1078,"changeRate":0.002671,"amplitude":0},"volumeRatio":1.0073369613100216,"impliedVol":0.0947,"impliedVolPercentile":0.588},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0073369613100216,"shares":200000,"dividePrice":0.3189,"high":40.7,"amplitude":0.02668,"preClose":40.1044,"low":39.63,"week52Low":24.9594,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":40.3622,"committee":-0.980198,"eps":0,"divideRate":0.007901,"volume":1675,"delay":0,"ttmEps":0,"open":40.7,"prevYearClose":32.3193,"prevWeekClose":39.6482,"prevMonthClose":36.6044,"prevQuarterClose":38.8263,"fiveDayClose":40.6657,"twentyDayClose":36.9977,"sixtyDayClose":35.4125},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650921135","title":"西藏首家高原腦機接口臨床應用中心成立","url":"https://stock-news.laohu8.com/highlight/detail?id=2650921135","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650921135?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 20:15","pubTimestamp":1783599334,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650948928","title":"資本瘋搶、玩家扎堆，腦機接口真的要來了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2650948928","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650948928?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 11:09","pubTimestamp":1783566589,"startTime":"0","endTime":"0","summary":"如果顺利上市，它将成为A股“脑机接口第一股”。）这些玩家们，证明着同一件事：脑机接口已经走出实验室了。2026年第一季度，国内脑机接口领域融资额已超过2025年全年。事实上，脑机接口概念并不新，但2025年被业内视为中国脑机接口技术正式步入临床的关键年。全球脑机接口相关企业已超过800家，主要集中在中国和美国。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783478066196157999","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160787890","title":"阿爾凱默斯與安尼爾終止授權仿製藥供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1160787890","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160787890?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 20:06","pubTimestamp":1783512380,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，阿尔凯默斯公司与其合作伙伴安尼尔公司已共同决定，自2026年7月6日起，终止双方此前达成的授权仿制药产品供应协议。\n这一变动标志着两家公司在该特定产品合作上的正式分道扬镳。协议的终止将影响相关仿制药未来的市场供应格局。文件披露了这一商业安排的调整，但未进一步阐述终止协议的具体原因或后续财务影响。\n市场参与者将密切关注此举对阿尔凯默斯业务管线及收入构成的潜在影响。同时，安尼尔公司的产品组合也可能因此次合作终止而面临调整。此次战略调整的长期影响，仍有待后续观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","IBRN","PSIL","PSCH","MEDX","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155767412","title":"阿爾凱默斯與安尼爾協議終止後，無需承擔罰金或額外義務——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155767412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155767412?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 20:06","pubTimestamp":1783512372,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件，阿尔凯默斯与安尼尔在协议终止后，双方均无需支付任何罚金，也无需履行进一步的义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","FBT","ALKS","IBRN","BK4139","MEDX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150710040","title":"Praxis Precision Medicines與Remagine Labs宣佈戰略合作，開發治療特發性震顫的透皮烏利沙卡他胺","url":"https://stock-news.laohu8.com/highlight/detail?id=1150710040","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150710040?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 20:02","pubTimestamp":1783425763,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines与Remagine Labs已达成一项战略合作，旨在共同开发用于治疗特发性震颤（Essential Tremor）的透皮制剂乌利沙卡他胺（Ulixacaltamide）。此次合作将结合双方在精准医疗与创新药物递送技术方面的专长，推进该疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0889565916.HKD","IBRN","IE00B4R5TH58.HKD","PRAX","IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649985281","title":"國內首款硬膜下植入式腦機接口產品啓動註冊臨床試驗，宣稱不傷腦、不燒腦","url":"https://stock-news.laohu8.com/highlight/detail?id=2649985281","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649985281?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 16:47","pubTimestamp":1783414057,"startTime":"0","endTime":"0","summary":"IT之家 7 月 7 日消息，脑虎科技今日宣布，其自主研发的“植入式脑机接口手部运动功能代偿系统”，即“全植入、全无线、全功能 脑机接口系统”在复旦大学附属华山医院正式启动 GCP 注册临床试验。这是国内首款进入国家三类医疗器械注册临床阶段的硬膜下皮层表面植入式脑机接口产品。本次 GCP 注册临床试验旨在评价该脑机产品用于颈段脊髓损伤所致四肢瘫痪患者上肢功能代偿的安全性和有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8uZJPagN8Wu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BMED","IBRN","MNTL","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649645900","title":"上半年上海腦機接口融資事件數量佔全國近60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649645900","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649645900?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 14:04","pubTimestamp":1783317858,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649979756","title":"「站在未來看今天，應做對什麼」","url":"https://stock-news.laohu8.com/highlight/detail?id=2649979756","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649979756?lang=zh_tw&edition=fundamental","pubTime":"2026-07-05 07:05","pubTimestamp":1783206300,"startTime":"0","endTime":"0","summary":"“快速迭代、抢占先机”1月31日，皖南医科大学第一附属医院完成安徽省首例植入式脑机接口手术，偏瘫患者凭借“意念”恢复右手抓握及喝水功能。4月9日，蚌埠医科大学第一附属医院神经外科手术室内，因急性脑梗致偏瘫5年的患者麻先生成功接受了安徽省首例半侵入式脑机接口植入手术。安徽省将脑机接口列为十大未来产业之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-07-05/doc-inifszci9668781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AIBU","09834","QMAR","GK","NEWZ","PSQ","NJAN","07261","09086","GPIQ","NOCT","07522","QQQX","MNTL","07266","KOMP","VGT","VUSE","07568","QQQ","QDEC","5RE.SI","TQQQ","QSWN","02834","AIFD","TARK","IBRN","NAPR","AGIX","OGIG","03086","BK4585","NBDS","SQQQ","MVPS","NJUL","TQQY","QQA","LCLG","03455","CPNQ","QLD","CHAT","QID","QTOC","QQQM","FWD","ARTY","03034"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648696901","title":"明視腦機陳文凱：感知重建視覺重建是腦機接口領域的「珠穆朗瑪峯」","url":"https://stock-news.laohu8.com/highlight/detail?id=2648696901","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648696901?lang=zh_tw&edition=fundamental","pubTime":"2026-07-04 15:32","pubTimestamp":1783150320,"startTime":"0","endTime":"0","summary":"　　7月3日-4日，2026亚布力论坛创新年会在上海市举行。本次创新年会的主题是“创新驱动 智启未来——十五五蓝图与企业机遇”。　　明视脑机首席商务官陈文凯表示，脑机接口的终极未来，一定是人类的一次重大升级，是碳基生命与硅基智能的深度融合，是人脑与AI的双向共生。再往长远推演，未来人机融合的核心趋势，就是人脑与AI的深度绑定。　　他认为，感知重建、视觉重建，是脑机接口领域的“珠穆朗玛峰”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-07-04/doc-inifrnzy3306745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":9,"totalSize":169,"code":"91000000","status":"200"}]}}